The Technical Analyst
9 Meters Biopharma Inc [NMTR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
9 Meters Biopharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-42.97% $0.0722
America/New_York / 25 jul 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.044 mill |
| EPS: | -1.690 |
| P/E: | -0.0427 |
| Earnings Date: | Aug 13, 2023 |
| SharesOutstanding: | 14.46 mill |
| Avg Daily Volume: | 0.446 mill |
| RATING 2023-08-21 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0427 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0427 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0581 - 0.0919 ( +/- 443.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-04-21 | Sensenig Bethany | Sell | 9 100 | Common stock |
| 2023-03-29 | Sirgo Mark A | Buy | 7 885 | Common Stock |
| 2023-03-29 | Rice Yehuda Michael | Buy | 7 885 | Common Stock |
| 2023-03-29 | Johnson Lorin K | Buy | 7 885 | Common Stock |
| 2023-03-29 | Constantino Michael T. | Buy | 7 885 | Common Stock |
| INSIDER POWER |
|---|
| 96.53 |
| Last 98 transactions |
| Buy: 58 384 829 | Sell: 18 657 625 |
Forecast:
01:40 - $0.151
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0722 (-42.97% ) |
| Volume | 4.59 mill |
| Avg. Vol. | 0.446 mill |
| % of Avg. Vol | 1 029.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NMTR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NMTR
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Latest Press Releases
2023-03-07 08:00:00 - Press Release
9 Meters Biopharma To Present At The Oppenheimer 33rd Annual Healthcare Conference
Raleigh, nc / accesswire / march 7, 2023 / 9 meters biopharma, inc. (nasdaq:nmtr), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that john temperato, president and chief executive officer of 9 meters, is scheduled to present at the oppenheimer 33rd annual healthcare conference. oppenheimer 33 rd annual healthcare conference date: monday, march 13, 2023 time: 3:20 pm et webcast link the presentation will highlight the company's pipeline, with a focus on vurolenatide, its long-acting glp-1 agonist in phase 3 development for short bowel syndrome, as well as upcoming milestones.
2023-01-31 08:00:00 - Press Release
9 Meters Biopharma To Present At The 2023 Bio Ceo & Investor Conference
Raleigh, nc / accesswire / january 31, 2023 / 9 meters biopharma, inc. (nasdaq:nmtr), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that john temperato, president and chief executive officer of 9 meters is scheduled to present on monday, february 6, 2023, at 10:00 am et as part of the bio ceo & investor conference being held in new york city. the presentation, which is accessible to registered conference attendees, will highlight the company's pipeline, with a focus on vurolenatide, its long-acting glp-1 agonist in phase 3 development for short bowel syndrome, as well as upcoming milestones.
2022-10-18 08:00:00 - Press Release
9 Meters Biopharma To Present At The American College Of Gastroenterology (acg) 2022 Annual Scientific Meeting
Raleigh, nc / accesswire / october 18, 2022 / 9 meters biopharma, inc. (nasdaq:nmtr), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the american college of gastroenterology (acg) 2022 annual scientific meeting taking place in charlotte, north carolina on october 21-26, 2022. the posters highlight preclinical data investigating the use of humanized monoclonal antibodies (hu-mabs) to glucose-dependent insulinotropic polypeptide (gip).
2022-05-05 08:00:00 - Press Release
9 Meters Biopharma To Present At The H.c. Wainwright Global Investment Conference And The Lifesci Partners Immunology & Inflammation Symposium
Raleigh, nc / accesswire / may 5, 2022 / 9 meters biopharma, inc. (nasdaq:nmtr), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that john temperato, president & chief executive officer of 9 meters, will present at the lifesci partners immunology & inflammation symposium on may 10, 2022, and the h.c. wainwright global investment conference to be held on may 23-26, 2022.
2022-03-21 08:00:00 - Press Release
9 Meters Biopharma To Present At The Maxim Group 2022 Virtual Growth Conference
Raleigh, nc / accesswire / march 21, 2022 / 9 meters biopharma, inc. (nasdaq:nmtr), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that john temperato, president & chief executive officer of 9 meters, will present at the maxim group 2022 virtual growth conference hosted by m-vest on march 28 - 30, 2022. maxim group 2022 virtual growth conference presentation: available for viewing on march 28 - 30, 2022 webcast: https://m-vest.com/events/2022-virtual-growth-conference/p/nmtr the presentation will also be available in the events section of the 9 meters website.
Latest News
2023-07-18 10:02:55 - Reuters
Drug developer 9 Meters Biopharma files for bankruptcy protection
Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.
2023-03-07 08:00:00 - Accesswire
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33 rd Annual Healthcare Conference Date: Monday, March 13, 2023 Time: 3:20 PM ET Webcast link The presentation will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.
2023-01-31 08:00:00 - Accesswire
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City. The presentation, which is accessible to registered conference attendees, will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.
2022-10-18 08:00:00 - Accesswire
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting taking place in Charlotte, North Carolina on October 21-26, 2022. The posters highlight preclinical data investigating the use of humanized monoclonal antibodies (hu-mAbs) to glucose-dependent insulinotropic polypeptide (GIP).
2022-09-27 14:17:21 - Zacks Investment Research
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
2022-07-04 14:00:00 - PennyStocks
How to Find Trending Penny Stocks in 2022
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-24 07:00:00 - PennyStocks
What to Know About Buying Penny Stocks on June 24th
Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-23 07:00:00 - PennyStocks
What to Know About Buying Penny Stocks on June 23rd
Here's what you need to know about trading penny stocks on June 23rd The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-21 10:25:06 - Benzinga
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. Based on consultation with the independent.
2022-05-05 08:00:00 - Accesswire
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.